Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: J Immunother. 2010 Oct;33(8):780–788. doi: 10.1097/CJI.0b013e3181ee6675

Figure 4. CAR-CCR2b ATCs show specificity towards GD2+ neuroblastoma and enhanced CCL2 migration.

Figure 4

A) ATCs modified with CAR-CCR2b shown increased migration towards SK-N-AS supernatant and rhCCL2 compared to NT ATCs. B) ATCs transduced with CAR-CCR2b specifically recognize and kill SK-N-AS tumor cells, whereas non-transduced (NT) control ATCs do not. C and D) Seven day co-culture assays comparing NT ATCs with ATCs transduced with CAR or with CAR-CCR2b at a 10:1 T cell to tumor ratio, demonstrating complete elimination of GFP+ SK-N-AS tumor cells by CAR and CAR-CCR2b transduced ATCs, respectively, but not by NT ATCs.